Impact of regional copayment policy on selective serotonin reuptake inhibitor (SSRI) consumption and expenditure in Italy
| Autor: | Gianfranco Damiani, Bruno Federico, Lanfranco Iodice, Alessandra Ronconi, Pierluigi Navarra, Roberto Da Cas, Angela Anselmi, Caterina Bianca Neve Aurora Bianchi, Giulia Silvestrini, Roberto Raschetti, Walter Ricciardi |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Drug Utilization
medicine.medical_specialty Cost Control Serotonin reuptake inhibitor Drug Costs Drug policy expenditure Deductibles and Coinsurance Drug utilization medicine Pharmacology (medical) Policy Making Psychiatry Serotonin Uptake Inhibitors Settore MED/42 - IGIENE GENERALE E APPLICATA Serotonin uptake inhibitors Pharmacology Consumption (economics) Copayment Public economics business.industry Antidepressive agents/therapeutic use Time trends General Medicine Serotonin reuptake Italy Cost control Antidepressant Health Expenditures business Selective Serotonin Reuptake Inhibitors |
| Zdroj: | European Journal of Clinical Pharmacology. 69:957-963 |
| ISSN: | 1432-1041 0031-6970 |
| Popis: | The continuous growth of antidepressant consumption and expenditure, especially for selective serotonin reuptake inhibitors (SSRIs), has led to the adoption of several policy measures directed toward cost control in Western countries. In Italy, copayment policies have been heterogeneously introduced at a regional level as part of a strategy designed to reduce drug consumption. The aim of our study was to evaluate whether regional copayment policies have affected trends in the consumption of and expenditure for SSRIs from 2001 to 2007.The consumption of SSRIs was measured in terms of defined daily doses per 1,000 inhabitants (DDD/1000) per day from May 2001 to December 2007. Time trends in consumption and expenditure before and after the introduction of copayment policies were examined using segmented regression analysis of interrupted time-series, adjusting for seasonal components. The study was conducted for 17 regions, nine of which had implemented a copayment policy.The overall consumption of SSRIs in Italy increased during the study period, from a monthly consumption of 12.85 DDD/1000 per day in May 2001 to 23.40 DDD/1000 per day in December 2007. The average monthly increase in SSRI use was 0.82 % in regions with a copayment policy versus 0.77 % in regions without a copayment policy (P = 0.329). According to the multivariable analysis, copayment was associated with a 1 % reduction in the monthly growth rate of SSRI consumption (P = 0.01). The impact of copayment on expenditure was statistically significant (P 0.005) on both the level and the trend, even though the estimate of the effect was negligible.The implementation of copayment policies in Italy affected both the use and expenditure of SSRIs between 2001 and 2007 to only to a minor extent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink